Drug-induced prolongation of the QT interval.
@article{Roden2004DruginducedPO,
title={Drug-induced prolongation of the QT interval.},
author={Dan M. Roden},
journal={The New England journal of medicine},
year={2004},
volume={350 10},
pages={
1013-22
}
}The single most common cause of the withdrawal or restriction of the use of marketed drugs has been QT-interval prolongation associated with polymorphic ventricular tachycardia, or torsade de pointes, a condition that can be fatal. This review summarizes the current knowledge about molecular and clinical predictors of drug-induced QT-interval prolongation and torsade de pointes and discusses how new molecular predictors of drug action might be incorporated into drug-development programs and…
745 Citations
Drug-induced QT prolongation: consequences and current dilemma.
- MedicineBritish journal of hospital medicine
- 2007
A case of extreme QT interval prolongation in association with drug therapy and the measures required to treat it is described.
Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine.
- MedicineInternational journal of cardiology
- 2006
QT interval prolongation and torsade de pointes associated with indapamide.
- MedicineInternational journal of cardiology
- 2006
Drugs and the QT interval - caveat doctor.
- MedicineThe New England journal of medicine
- 2004
During the past few years, many drugs have been removed from the market or required to include “black box” warnings on their labels because of the potential for QT-interval prolongation.
Genetics of acquired long QT syndrome.
- Medicine, BiologyThe Journal of clinical investigation
- 2005
The molecular and cellular mechanisms underlying this acquired or drug-induced form of long QT syndrome are summarized, approaches to the analysis of a role for DNA variants in the mediation of individual susceptibility are described, and it is proposed that these concepts may be generalizable to common acquired arrhythmias.
[Proarrhythmic adverse effects of nonarrhythmic drugs].
- MedicineHerzschrittmachertherapie & Elektrophysiologie
- 2019
During drug prescription, it is necessary to monitor QTc with regular ECGs and end of drug administration followed by monitoring of the patient according to the individual risk for TdP.
Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes
- MedicinePharmacoepidemiology and drug safety
- 2009
Values inferred from a population that predict a stronger potential for drug induced TdP are identified.
QT interval prolongation associated with venlafaxine administration.
- Medicine, PsychologyInternational journal of cardiology
- 2006
Drug-Induced QT Prolongation
- Medicine
- 2015
It is imperative that the clinician be aware of which drugs commonly used in the perioperative setting may cause QT prolongation as well as the unique treatments for management of torsades de pointes beyond standard resuscitative measures.
References
SHOWING 1-10 OF 88 REFERENCES
Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.
- MedicineAmerican heart journal
- 1986
Evidence for a Cardiac Ion Channel Mutation Underlying Drug‐Induced QT Prolongation and Life‐Threatening Arrhythmias
- Medicine, BiologyJournal of cardiovascular electrophysiology
- 2000
It is demonstrated that some cases of drug‐induced QT prolongation may depend on a genetic substrate, and molecular screening may allow identification among family members of gene carriers potentially at risk if treated with Ikr blockers.
Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients.
- MedicineJournal of the American College of Cardiology
- 1983
A common polymorphism associated with antibiotic-induced cardiac arrhythmia.
- Biology, MedicineProceedings of the National Academy of Sciences of the United States of America
- 2000
It is concluded that allelic variants of MiRP1 contribute to a significant fraction of cases of drug-induced LQTS through multiple mechanisms and that common sequence variations that increase the risk of life-threatening drug reactions can be clinically silent before drug exposure.
Exaggerated QT prolongation after cardioversion of atrial fibrillation.
- MedicineJournal of the American College of Cardiology
- 1999
Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes
- Psychology, MedicinePacing and clinical electrophysiology : PACE
- 1998
Progress toward understanding mechanisms underlying torsades de pointes and identifying patients at risk would go a long way to rationalizing therapy with currently available antiarrhythmic drugs and perhaps directing development of new agents.
The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis
- Medicine, BiologyJournal of cardiovascular pharmacology
- 2001
This Purkinje fiber model detects six of seven drugs linked clinically to acquired long QT syndrome and torsade de pointes, and clears each of five drugs not associated with repolarization abnormalities (overall 92% accuracy), validating the utility of this Purkinjen fiber model in the preclinical evaluation of QT prolongation and proarrhythmic risk by noncardiac drugs.
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
- MedicineJAMA
- 1993
It is strongly suggested that women are more prone than men to develop torsades de pointes during administration of cardiovascular drugs that prolong cardiac repolarization.
Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias
- Biology, MedicineJournal of cardiovascular pharmacology
- 2001
It is concluded that I Kr blocking potency can be readily assessed in either AT-1 cells or systems in which HERG is heterologously expressed, and not all drugs causing TdP are potent I Kr blockers, and I Kr block is not necessarily associated with Td P.
Quinidine Syncope: Paroxysmal Ventricular Fibrillation Occurring during Treatment of Chronic Atrial Arrhythmias
- MedicineCirculation
- 1964
The purpose of this communication is to focus attention on syncopal attacks occurring during quinidine therapy and apparently related to paroxysms of ventricular flutter or fibrillation.



